Insights on the Glycogen Synthase Kinase 3 Beta Market to 2027 | Industry Statistics, Emerging Demands, Forecast to 2027

The global glycogen synthase kinase 3 beta market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Glycogen synthase kinase 3, or GSK-3 refers to a serine/threonine, proline-directed kinase that is associated with a diverse array of signaling pathways, which includes cellular adhesion and glycogen synthesis. The compounds derived from natural sources come mainly from plants or marine organisms, and include Indirubin, Hymenialdisine, Meridianins, Manzamines, Palinurin, and Tricantin. Another promising opportunity for the market growth includes the favorable outcome of the glycogen synthase kinase 3 beta in the treatment of bipolar disorder. As per the Institute for Health Metrics and Evaluation (IHME), Global Burden of Diseases, the prevalence of bipolar disorder across the world varies from 0.3 to 1.2% by country. In 2017, around 46 million people around the globe had bipolar disorder, with 52% and 48% being female and male, respectively. The typical age of onset is the late teens or the early 20s, and a history of depression is common in people diagnosed with bipolar.

To Request a Sample of our Report on Glycogen Synthase Kinase 3 Beta Market: https://www.omrglobal.com/request-sample/glycogen-synthase-kinase-3-beta-market

The major factor primarily attributed to the market growth include the growing use of these inhibitors in in vivo models and in numerous clinical trials. Since 2011, substantial developments in glycogen synthase kinase 3 beta were witnessed in the form of products that include AZD1080 from AstraZeneca and LY2090314 from Eli-Lilly (both ATP competitive inhibitors). Unfortunately, their development was discontinued due to safety issues. Further, glycogen synthase kinase beta is further likely to be used in the treatment of musculoskeletal disorder, lung cancer, dyskinesia, and Menkes disease, among others.

Some key players operating in the market include AstraZeneca plc, Eli Lilly and Co., and Santa Cruz Biotechnology, Inc., among others.

Market Coverage

· The market number available for - 2020-2027

· Base year- 2020

· Forecast period- 2021-2027

Segment Covered-

· By Type

· By Indication

Regions covered-

· North America

· Europe

· Asia-Pacific

· Rest of the World

Competitive Landscape: AstraZeneca plc, Eli Lilly and Co., and Santa Cruz Biotechnology, Inc., among others.

(Get 15% Discount on Buying this Report)

A full Report of Glycogen Synthase Kinase 3 Beta Market is Available @ https://www.omrglobal.com/industry-reports/glycogen-synthase-kinase-3-beta-market

Global Glycogen Synthase Kinase 3 Beta Market Report by Segment

By Type

• AZD1080

• LY2090314

• AP-001

• AP-1

• DM-204

• Neu-120

• Others

By Indication

• Musculoskeletal Disorder

• Lung Cancer

• Dyskinesia

• Menkes Disease

• Inflammatory Disease

• Others

Global Glycogen Synthase Kinase 3 Beta Market Report by Region

North America

· United States

· Canada

Europe

· UK

· Germany

· Spain

· France

· Italy

· Rest of Europe

Asia-Pacific

· India

· China

· Japan

· South Korea

· Rest of APAC

Rest of the World

· Latin America

· Middle East & Africa

Reasons to buy from us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.